Hello, everyone, and how are you today? A shiny sun is warming the chilly Pharmalot campus this morning, where the officials mascots are happily snoozing. As for us, we are staring at an intimidating to-do list and quaffing cups of stimulation. Perhaps you can relate? In any event, we have once again assembled a few items of interest to get you started on your day. So here you go. Hope you conquer the world and keep us in mind when you run across something intriguing…

Prime Therapeutics is the latest pharmacy benefits manager to refuse to cover Auvi-Q, the relaunched rival to EpiPen, over its $4,500 list price. “Consumers and payers are simply being taken advantage of when products are 100 percent to 1,500 perent more expensive than comparable products,” says Prime chief financial officer Alec Mahmood. He insisted PBMs and payers are “a critical counterweight to this egregious behavior.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy